Avicenna at MDIC Real-World Evidence Summit

Among them were our Research & Technology Working Group Leader, Prof. Liesbet Geris (VPH Institute), our In Silico Application (ISA) Working Group Leader, Dr. Cécile Rousseau (Voisin Consulting Life Sciences (VCLS)), the Avicenna UK In Silico Regulatory Innovation Task Force co-Chair, Prof. Alex Frangi (University of Manchester), the Avicenna Nonclinical Application Task Force co-Chair, Dr. Julien Clin (Numalogics), and the newly appointed co-chair of the Global Harmonization Task Force, Dr. Tina Morrison (EQTY Labs).

A big thank you to Dr. Pras Pathmanathan (FDA), Dr. Cheryl Liu (Stryker) and the MDIC team for organizing this fantastic symposium bringing together great speakers, regulators, industry leaders, and innovators to explore the latest advancements and challenges in CM&S —an increasingly indispensable tool for accelerating medical device evaluation and transforming regulatory science.

The presence of representatives from FDA, MHRA, and PMDA highlighted the global commitment to integrating CM&S into regulatory frameworks, signalising a shared vision for harmonized approaches and standards that foster innovation while ensuring patient safety.

We are proud to see our members and partners actively shaping these discussions, reinforcing the Avicenna Alliance’s mission toposition in silico medicine and advanced modelling as key enablers for evidence generation, regulatory convergence, and patient-centric healthcare innovation worldwide.

Looking ahead, the Avicenna Alliance will continue to work closely with global stakeholders to develop standards, best practices, and collaborative initiatives that accelerate the adoption of in silico methods (CM&S and AI) and pave the way for international regulatory harmonization.